Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891888 | 1.00 | ALDH1A1 (0.65) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL5715714 | 0.98 | ALDH1A1 (0.61) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL29749177 | 0.96 | ALDH1A1 (0.65) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL29893113 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL5715880 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL2847536 | 0.82 | HTR1A (0.52) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL14922278 | 0.82 | ALDH1A1 (0.61) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL28224399 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL22653985 | 0.82 | ALDH1A1 (0.44) | ALDH1A1HTTGAASMN1; SMN2MAPT | |
| SCHEMBL5716060 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HTTGAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-1252166-B1 | OLEFIN POLYMERIZATION COCATALYSTS DERIVED FROM GROUP-15 CATIONIC COMPOUNDS AND PROCESSES USING THEM | EXXONMOBIL CHEM PATENTS INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6822057-B2 | OLEFIN POLYMERIZATION CATALYST SYSTEM IS A REACTION PRODUCT OF A METALLOCENES AND A COCATALYST CONTAINING FLUOROARYL SUBSTITUTED SECONDARY AMINE OR PHSOPHINE COMPOUND AND AN ANION CONTAINING GROUP 13 ELEMENT WHICH IS NONCOORDINATIG | EXXON MOBIL CHEMICAL PATENTS INC. | 2004-11-23 | — | — | US | disclosed |
| US-6489480-B2 | COORDINATION POLYMERIZATION CATALYST FOR ALPHA-OLEFINS | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020115806-A1 | Olefin polymerization catalysts derived from Group-15 cationic compounds and processes using them | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-08-22 | — | — | US | disclosed |
| US-20020111265-A1 | GROUP-15 CATIONIC COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | ALDH1A1 1997/4885HTT 802/4885GAA 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.